TScan Therapeutics, Inc. (TCRX) Stock Score, Valuation & Financial Research
TScan Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for TCRX
TScan Therapeutics, Inc. currently has a Wall Street Score of 19/100. The stored market price is $0.32. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What TScan Therapeutics, Inc. does
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T
TCRX financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $0.32
- Market capitalization:
- $19.6M
- Revenue:
- $7.1M
- Net income:
- $-117.7M
- Free cash flow:
- $-139.7M
- Cash:
- $100.2M
- Total debt:
- $90.9M
- EPS:
- -0.91
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 4/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $-139.7M, showing cash burn in the current stored period.
- The balance sheet shows $100.2M of cash versus $90.9M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.2 points: TCRX increased 0.2 points because overall fundamentals improved.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research TCRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.